newsfilter
← Latest News
Business Wire·

bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues

  • bioAffinity Technologies reported CyPath® Lung sales volume growth of over 200% year-over-year for Q2 2026.
  • Q2 2026 sales increased by more than 30% compared to the record-breaking Q1 2026.
  • Physician offices ordering CyPath® Lung increased by 155% in Q2 2026 compared to Q2 2025.
  • Nearly 3,000 CyPath® Lung tests have been performed since the commercial launch.
  • Growth is driven by increased utilization among existing clients rather than solely new practice onboarding.
  • The test is being adopted across pulmonology practices, lung nodule clinics, academic centers, community medical centers, & VA facilities.
  • Clinical data shows 92% sensitivity, 87% specificity, 88% accuracy, & 99% negative predictive value for detecting lung cancer in high-risk patients with nodules under 20mm.
  • bioAffinity Technologies plans to expand CyPath® Lung use for monitoring lung cancer survivors & develop tests for asthma & COPD.
  • The company expects to report Q2 2026 financial results in August.